Recruiting
Phase 2

Timolol

Sponsor:

Keith G. LeBlanc, Jr, MD

Code:

NCT05114239

Conditions

Wound Heal

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Interventions

Timolol 0.25% Ophthalmic Solution

Standard Wound Care

Study Details

Brief summary:

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the literature. The investigators will enroll 30 participants in a split scar study who have their skin cancer surgically removed resulting in a linear wound equal to or longer than 4cm. The objective of this randomized study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in wound closed primarily greater than or equal to 1.5 cm.

Conditions

Wound Heal

Study ID

NCT05114239

Start date

Apr 7, 2021

Status verified date

Oct, 2021

Completion date

Dec, 2022

Anticipated

Primary completion date

Sep, 2022

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

  • skin wounds greater than or equal to 4cm, closed primarily and linearly following standard excision or Mohs

Exclusion Criteria:

  • Past medical history of psoriasis
  • known history of sensitivity to beta blockers or topical timolol
  • pregnant women

Study Design

Enrollment

30 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Timolol

Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.

placebo comparator: Standard Wound Care

Petrolatum ointment

Interventions

Timolol 0.25% Ophthalmic Solution

Applied to treatment side prior to standard wound care

Standard Wound Care

Wound is washed twice a day with soap and then petrolatum and a bandage is applied.

Primary outcome measure

  • Observed cosmetic difference of scar in treatment side versus control: Yes or no [ Time Frame: 1 month after suture removal ]
  • Observed cosmetic difference of scar in treatment side versus control: Yes or no [ Time Frame: 3 months after suture removal ]

Central Contacts and Locations

Central contacts

Taylor G Dickerson, MD

(504) 568-7110tgrif3@lsuhsc.edu

Keith LeBlanc, MD

(504) 644-4226klebl2@gmail.com

Locations

Skin Surgery Centre

Recruiting

Metairie, Louisiana, United States, 70005

Contacts

Taylor G Dickerson, MD

225-955-3679tgrif3@lsuhsc.edu

Keith Leblanc, MD

504-644-4226kleb12@lsuhsc.edu

Principal Investigator:

Keith Leblanc, MD

More Information

Sponsor

Keith G. LeBlanc, Jr, MD

Last update posted

Nov 9, 2021

Last verified

Oct, 2021

Keywords

  • Timolol
  • Wound healing
  • Surgical Wounds

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Keith G. LeBlanc, Jr, MD on 2021-11-09.